Thomson Reuters Names Most Promising Drugs of 2015

PHILADELPHIA, March 23, 2015 /PRNewswire/ -- The Intellectual Property and Science business of Thomson Reuters, the world's leader in intelligent information for businesses and professionals, today released the 2015 edition of its annual Drugs to Watch report. The study reveals a significant increase in the number of expected blockbusters from three drugs in 2014 to eleven in 2015. Three of the new drugs are expected to reach more than $3 billion in sales by 2019. Thomson Reuters analysts utilized  Cortellis™ Competitive Intelligence—the pharmaceutical industry's leading source for drug pipeline, deals, patents, and company content—to forecast the new-to-market drugs expected to lead the pack in sales and potentially emerge as blockbusters (earning $ 1 billion+) by 2019.

The analysis spotlights the following 11 potential blockbusters, ranked by highest sales forecasts:

Drugs to Watch

Company

Therapy Area

2019 Sales Forecast in 
U.S. $ billions)

Opdivo (nivolumab)

Bristol-Myers Squibb

Melanoma

5.684

Praluent (alirocumab)

Regeneron Pharmaceuticals and Sanofi

Hypercholesterolemia

4.414

LCZ-696 (sacubitril and valsartan)

Novartis

chronic heart failure

3.731

Ibrance (palbociclib)

Pfizer

breast cancer

2.756

lumacaftor plus ivacaftor

Vertex Pharmaceuticals

cystic fibrosis

2.737

Viekira Pak (veruprevir, ritonavir, ombitsvir and dasabuvir)

AbbVie

hepatitis C

2.500

evolocumab

Amgen and Astellas Pharma

hypercholesterolemia/ hypherlipidemia

1.862

Gardasil 9

Merck & Co.

HPV Vaccine

1.637

brexpiprazole

Otsuka Pharmaceutical and Lundbeck

schizophrenia and depression

1.353

Toujeo (new-formulation insulin glargine)

Sanofi

Diabetes

1.265

Cosentyx (secukinumab)

Novartis

psoriasis and psoriatic arthritis

1.082

"This year's forecast identifies a substantial increase in the number of predicted blockbusters, inviting discussion around the current status of the blockbuster model," said Wendy Hamilton, global head of Life Sciences at Thomson Reuters. "As the pharmaceutical industry navigates constantly evolving revenue streams, this report serves as a valuable resource for identifying the therapies with the strongest sales potential."

To learn more about the year's most promising treatments, view 2015 Drugs to Watch. Learn more about Cortellis for Competitive Intelligence.

Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. For more information, go to www.thomsonreuters.com.

Jen Breen
+1 215 823 1791
[email protected]

Molly Malone
+1 215 823 3702
[email protected]

 

SOURCE Thomson Reuters

 

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.